Valuation: Onconic Therapeutics Inc.

Market Cap 574B 403M 350M 326M 299M 566M 38.29B 572M 3.84B 1.5B 19.14B 1.51B 1.48B 63.42B P/E 2024
-16.5x
P/E 2025 56.2x
Enterprise Value 522B 366M 318M 296M 272M 514M 34.78B 520M 3.49B 1.36B 17.39B 1.37B 1.34B 57.61B EV / Sales 2024
9.02x
EV / Sales 2025 15.3x
Free-Float
50.87%
Yield 2024 *
-
Yield 2025 -
1 day+12.54%
1 week+22.70%
Current month+16.91%
1 month+0.08%
3 months-41.16%
6 months-26.62%
Current year-35.29%
1 week 8,800
Extreme 8800
12,930
1 month 8,790
Extreme 8790
15,150
Current year 8,790
Extreme 8790
28,900
1 year 5,662.5
Extreme 5662.499999
28,900
3 years 3,137.5
Extreme 3137.5
28,900
5 years 3,137.5
Extreme 3137.5
28,900
10 years 3,137.5
Extreme 3137.5
28,900
Manager TitleAgeSince
Chief Executive Officer 59 2019-12-31
Director of Finance/CFO 50 2019-12-31
Chief Tech/Sci/R&D Officer 59 -
Director TitleAgeSince
Director/Board Member 50 2019-12-31
Director/Board Member 59 2019-12-31
Director/Board Member 44 2024-03-25
Date Insider Type Main position Quantity % Market Cap.
4/22/25 Fiscal year 50,000 0.4595%
4/18/25 Fiscal year

Chief Technology Officer

12,500 0.1149%
4/17/25 Fiscal year

Chief Financial Officer

18,100 0.1663%
Change 5-day change 1-year change 3-year change Capi.($)
+12.54%+22.70%+106.95% - 357M
+10.00%+14.90%+53.89%+87.07% 56.7B
+0.80%-5.70%+23.89%+62.65% 51.97B
-0.98%-1.19%-16.98%-14.21% 23.33B
+0.30%-5.17%-11.23%+349.07% 21.34B
+1.73%-1.57%+32.81%-25.80% 17.44B
+4.29%+8.97%+200.03%+341.85% 14.77B
+1.70%-2.37%+12.19%+604.06% 14.53B
+1.71%-0.90%+52.13%+176.27% 13.84B
+4.16%+4.44%+444.12%+183.06% 12.12B
Average +3.54%+3.82%+89.78%+196.00% 22.64B
Weighted average by Cap. +3.43%+1.36%+59.66%+147.52%

Financials

2024 2025
Net sales 14.84B 10.4M 9.03M 8.42M 7.73M 14.63M 989M 14.79M 99.25M 38.8M 494M 39.05M 38.19M 1.64B 53.39B 37.42M 32.49M 30.29M 27.83M 52.63M 3.56B 53.21M 357M 140M 1.78B 141M 137M 5.9B
Net income -8.09B -5.67M -4.92M -4.59M -4.22M -7.98M -539M -8.06M -54.13M -21.16M -270M -21.3M -20.83M -894M 15.78B 11.06M 9.6M 8.95M 8.23M 15.56M 1.05B 15.73M 106M 41.27M 526M 41.54M 40.63M 1.74B
Net Debt -42.69B -29.92M -25.98M -24.22M -22.25M -42.08M -2.85B -42.54M -286M -112M -1.42B -112M -110M -4.71B -52.61B -36.87M -32.01M -29.85M -27.42M -51.86M -3.51B -52.43M -352M -138M -1.75B -138M -135M -5.81B
Logo Onconic Therapeutics Inc.
Onconic Therapeutics Inc is a Korea-based company principally engaged in the new drugs research and development business. The Company mainly develops new drugs and treatments in the acid-related diseases, digestive diseases and anticancer fields based on small molecules. The Company’s products include acid-related disease treatment drug Zastaprazan and synthetic lethal deoxyribonucleic acid (DNA) damage repair inhibitor anticancer drug Nesuparib.
Employees
-
Date Price Change Volume
26-08-04 ₩12,650.00 +12.54% 785,874
26-08-03 ₩11,240.00 +3.88% 228,820
26-07-31 ₩10,820.00 +13.77% 323,305
26-07-30 ₩9,510.00 -0.11% 315,901
26-07-29 ₩9,520.00 -7.66% 507,083
  1. Stock Market
  2. Stocks
  3. A476060 Stock